King Faisal Specialist Hospital and Research Center
Riyadh, Saudi Arabia
4 recruiting
Showing 1–4 of 4 trials
Recruiting
Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Cardiovascular DiseasesHypertensionDiabetes Mellitus, Type 2
Boehringer Ingelheim11,800 enrolled1153 locationsNCT07064473
Recruiting
Phase 3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Heart Failure
Boehringer Ingelheim4,200 enrolled641 locationsNCT06935370
Recruiting
Phase 3
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Heart Failure
Boehringer Ingelheim6,000 enrolled652 locationsNCT06424288
Recruiting
Phase 1
CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia
Relapsed Refractory Acute Lymphoblastic Leukemia
King Faisal Specialist Hospital & Research Center24 enrolled1 locationNCT07361029